We are migrating the content of this website during the first semester of 2014 into the new EUR-Lex web-portal. We apologise if some content is out of date before the migration. We will publish all updates and corrections in the new version of the portal.
Do you have any questions? Contact us.
European Monitoring Centre for Drugs and Drug Addiction
This regulation recasts the founding regulation of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), providing the centre with an extended mandate. The centre is responsible for supplying the European Union (EU) and its countries with objective, reliable and comparable data on drugs and drug addiction and its consequences at the European level.
Regulation (EC) No 1920/2006 of the European Parliament and of the Council of 12 December 2006 on the European Monitoring Centre for Drugs and Drug Addiction (recast).
Council Regulation (EEC) No 302/93 on the establishment of a European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) had to be recast to keep abreast of new developments in the European Union (EU). The regulation also needed updating so as to extend the centre's role to the investigation of new trends in drug use, especially poly-drug use, where illicit drugs are taken in combination with legal drugs or medication.
Role and activities
The role of EMCDDA is to process and produce statistical, documentary and technical information on drugs and drug addiction, and thereby provide the EU and its countries with an overall view of the European drugs situation when they take measures or devise activities in their respective spheres of responsibility. The centre may not go beyond this overall information brief and must not collect personal data.
This recast regulation strengthens the centre's role. It extends the centre’s collection, registration and analysis work to also cover data on emerging trends in drug use. The regulation underlines the importance of exchanging information on best practices developed in EU countries.
The priority areas of EMCDDA activities consist of:
- monitoring the state of the drugs problem and emerging trends, in particular those involving poly-drug use;
- monitoring the solutions applied to drug-related problems, providing information on best practices in EU countries and facilitating the exchange of such practices among them;
- maintaining a rapid information system and assessing the risks of new psychoactive substances;
- developing tools and instruments to help the Commission and EU countries to monitor and evaluate their respective policies on drugs.
The organisation and working methods of EMCDDA are defined in such a way as to ensure the objectivity of the results sought, i.e. the comparability of sources and methods concerning information on drugs. Its activities in this framework can be summarised as follows:
- collection and analysis of existing data;
- improvement of data-comparison methods;
- dissemination of data;
- cooperation with European and international organisations and non-EU countries;
- dissemination of information on new developments and trends.
The centre is assisted by a scientific committee.
The centre also has at its disposal the European Information Network on Drugs and Drug Addiction (Reitox). The network consists of one focal point for each EU country and for each country that has concluded an agreement on participation in EMCDDA, as well as of a focal point for the Commission.
The centre must take account of activities already carried out by other agencies, e.g. the European Police Office (Europol).
Legal and organisational status
The centre has legal personality. Any actions brought against it fall under the jurisdiction of the Court of Justice of the European Union (EJC). The centre’s headquarters are in Lisbon, Portugal.
EMCDDA is headed by a director, who is responsible for the centre’s daily management. The management board, which is assisted by an executive committee, adopts the centre’s:
- three-year work programmes;
- annual work programmes (under the three-year work programmes);
- annual activity reports.
EMCDDA is also open to non-EU countries that attach the same importance as the EU and its countries to the issue of drugs. The regulation specifies the status of members representing these countries on the management board.
The centre is to gradually achieve its aims, in light of the objectives laid down in the three-year and annual work programmes and with due regard to the resources available. Every six years the Commission will conduct an external evaluation that must also cover the Reitox network.
|Act||Entry into force||Deadline for transposition in the Member States||Official Journal|
Regulation (EC) No 1920/2006
OJ L 376, 27.12.2006
- The EMCDDA website